Senti Biosciences Issues $4.0M Senior Secured Convertible Notes

What Happened

• Senti Biosciences Holdings, Inc. (through its wholly owned subsidiary Senti Holdings, Inc.) filed an 8‑K on Aug 20, 2026 reporting that on Aug 14, 2026 it issued and sold $4.0 million in aggregate principal amount of Senior Secured Convertible Notes to Celadon Partners SPV 24 pursuant to a Securities Purchase Agreement dated April 27, 2026.

Key Details

• Issuer: Senti Holdings, Inc. (wholly owned subsidiary of Senti Biosciences Holdings, Inc.).
• Buyer: Celadon Partners SPV 24.
• Amount: $4.0 million aggregate principal of Senior Secured Convertible Notes.
• Agreement referenced: Securities Purchase Agreement dated April 27, 2026 among the Company, Senti Holdings, Senti Biosciences, Inc., and Celadon.

Why It Matters

• This 8‑K documents a material financing transaction (Item 1.01) and the creation of a new direct financial obligation (Item 2.03) for the company. The issuance increases the company’s debt in the form of senior secured convertible notes and could affect the company’s capital structure and future liquidity depending on the notes’ terms and any conversions. Investors should review the full Securities Purchase Agreement and the note terms (as filed) to understand interest, maturity, conversion mechanics and any security or covenants.